R&D Views & Analysis | pharmaphorum

Views & Analysis

R&D

How Design of Experiments enriches life sciences’ findings

Design of Experiments (DOE) is a methodology misunderstood by many, understood by some, and actively used by even fewer than that.

Patients

Pharma Integrates London 2022 Tower Bridge

A glance back to Pharma Integrates, London 2022 – part ii

Run by Life Science Integrates, Pharma Integrates was in its 11th year in 2022.

News

A glance back to Pharma Integrates 2022 – part i

Run by Life Science Integrates, Pharma Integrates was in its eleventh year in 2022.

R&D

Why early participant engagement is now a top priority in ge...

In 2016, scientists behind a study called the Resilience Project analysed genetic data from 589,000+ people and found 13 adults who carried genetic variants that should have resulted in ser

R&D

Taking an ‘upside-down’ approach to mRNA delivery

Ben Hargreaves speaks to Liberate Bio, a company that is hoping to address the delivery issues that could prevent mRNA, as well as siRNA and ASO therapeutics, from reaching their full poten

Patients

Nine for 2023, part two: healthcare’s hard problem, the prog...

The first part of IQVIA EMEA Thought Leadership’s Nine for 2023 three-part series, focusing on issues that will change the direction of healthcare and the pharmaceutical industry this year,